Market open
$
25.27
Change
-0.35 -1.35%
Volume
Volume 456,042
Aug 18, 2022, 1:34 p.m.
Real time quotes
Previous close
$ 25.61
$ 25.27
Change
-0.35 -1.35%
Day low
Day high
$25.19
$25.78

52 week low
52 week high
$21.24
$33.00

Market cap
$4.21B
Average volume
1.56M
P/E ratio
N/A
Rev. per Employee
$530,696
EPS
-0.58
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on ALKS
-
How to Avoid the Biotech Bear Market: Get Some Products Approved
- Barron's Online
-
Biotech Stocks Are Having a Terrible Year. These 10 Are Still Winning.
- Barron's Online
-
Nektar Shares Halve on Cancer Trial Failure
- Barron's Online
-
Alkermes downgraded to underperform from neutral at BofA Securities
- Tomi Kilgore
-
Alkermes stock halted for news pending
- Tomi Kilgore
-
Biotech Is Down. How It Could Come Back.
- Barron's Online
-
The Case for AbbVie as a Top Biopharma Stock in 2021
- Barron's Online
-
Alkermes upgraded to buy from neutral at Mizuho
- Tomi Kilgore
-
Alkermes stock price target raised to $24 from $19 at Mizuho
- Tomi Kilgore
-
Alkermes downgraded to neutral from buy at BofA Securities
- Tomi Kilgore
-
Alkermes stock price target cut to $20 from $31 at BofA Securities
- Tomi Kilgore
-
Alkermes downgraded to neutral from overweight at J.P. Morgan
- Tomi Kilgore
-
Alkermes stock price target cut to $21 from $25 at J.P. Morgan
- Tomi Kilgore
-
FDA told Alkermes to stop publishing Vivitrol ad
- Jaimy Lee
-
Alkermes to acquire Rodin Therapeutics for up to $950 million
- Ciara Linnane
-
- Jaimy Lee
-
Biogen, Alkermes MS treatment Vumerity gets FDA approval
- Tomi Kilgore
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For February 22, 2018
- Benzinga.com
-
Your Cheat Sheet For Q1 Biotech Earnings
- Benzinga.com
Other News on ALKS
-
3 Companies Growing Revenue Fast
- GuruFocus.com
- Loading more headlines...
Press Releases on ALKS
-
Alkermes plc Reports Second Quarter 2022 Financial Results
- PR Newswire - PRF
-
Alkermes to Report Second Quarter Financial Results on July 27, 2022
- PR Newswire - PRF
-
Alkermes Announces Results of Annual General Meeting of Shareholders
- PR Newswire - PRF
-
Sarissa Capital Comments on Alkermes Annual Meeting
- BusinessWire - BZX
-
Alkermes to Participate in the Goldman Sachs Healthcare Conference
- PR Newswire - PRF
-
Alkermes to Participate in the Jefferies Healthcare Conference
- PR Newswire - PRF
-
Sarissa Condemns Poor Corporate Governance at Alkermes
- BusinessWire - BZX
-
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
- Financial News Media
-
Alkermes to Report First Quarter Financial Results on April 27, 2022
- PR Newswire - PRF
-
Alkermes to Participate in the Stifel 2022 CNS Days
- PR Newswire - PRF
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com